ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
Last trade$7.72
Day change+$0.20 (+2.66%)
Day range$7.54 – $8.08
Volume1,017,592
Market cap$779M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$779.47M
Price / earnings
—
Price / book
2.04×
Price / sales
—
EV / sales
—
EV / EBITDA
-4.79×
Profitability
Earnings per share
-$1.35
Return on assets
-34.68%
Return on equity
-36.81%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
13.19×
Quick ratio
13.19×
Cash ratio
1.81×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$112.26M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ORIC, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Q3 FY2024 Sep 30, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$9M
$8.18M
$8.7M
$7.9M
$8.52M
$8.08M
$7.6M
$7.12M
Research and development
$36.3M
$31.44M
$25.86M
$28.77M
$30.55M
$24.64M
$31.97M
$31.2M
Total operating expenses
$45.3M
$39.62M
$34.55M
$36.67M
$39.06M
$32.72M
$39.57M
$38.32M
Operating income
-$45.3M
-$39.62M
-$34.55M
-$36.67M
-$39.06M
-$32.72M
-$39.57M
-$38.32M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$41.49M
-$35.77M
-$30.51M
-$32.59M
-$36.36M
-$30.02M
-$36.31M
-$34.57M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$41.49M
-$35.77M
-$30.51M
-$32.59M
-$36.36M
-$30.02M
-$36.31M
-$34.57M
Net income attributable to common shareholders
-$41.49M
-$35.77M
-$30.51M
-$32.59M
-$36.36M
-$30.02M
-$36.31M
-$34.57M
EBITDA
-$45.03M
-$39.35M
-$34.23M
-$36.38M
-$38.75M
-$32.42M
-$39.27M
-$38.05M
Basic earnings per share
-$0.38
-$0.34
-$0.30
-$0.33
-$0.47
-$0.42
-$0.51
-$0.49
Diluted earnings per share
-$0.38
-$0.34
-$0.30
-$0.33
-$0.47
-$0.42
-$0.51
-$0.49
Recent news
Company coverage with links to the original publishers.
ORIC Pharmaceuticals announced preclinical and translational data showing rinzimetostat, a PRC2 inhibitor targeting the EED subunit, enhances sensitivity to androgen receptor inhibition in prostate cancer. The data demonstrates advantages over EZH2 inhibitors, including resistance to resistance mutations, favorable drug properties, and mechanistic proof-of-concept in patient samples. Results support continued development in the ongoing Himalayas-1 Phase 3 trial.
ORIC Pharmaceuticals announced promising Phase 1b data for enozertinib in first-line EGFR atypical NSCLC patients, demonstrating 84% confirmed systemic ORR and 70% confirmed intracranial ORR, with an 88% 6-month landmark PFS. The company plans to initiate the Redwood-1 global Phase 3 registrational trial in 1H 2027, enrolling approximately 360 patients.
ORIC Pharmaceuticals granted 125,400 non-qualified stock options and 20,550 restricted stock units to five new non-executive employees as inducement for employment. The grants were approved by the Compensation Committee and comply with Nasdaq Rule 5635(c)(4). The company continues development of its clinical-stage oncology candidates including rinzimetostat for prostate cancer and enozertinib for NSCLC.
Pomerantz LLP is investigating potential securities fraud claims against ORIC Pharmaceuticals following a 41% stock price decline on March 31, 2026. The drop occurred after the company announced that its prostate cancer treatment (rinzimetostat/ORIC-944) performed roughly as effectively as competitors, falling short of expectations that it would be the best-in-class PRC2 blocker.
ORIC Pharmaceuticals announced equity inducement grants of 80,000 non-qualified stock options and 15,000 restricted stock units to a new non-executive employee hired in March 2026. The grants were approved by the Compensation Committee under Nasdaq Rule 5635(c)(4) and vest over time based on continued employment.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.